Back
Results - Announcements
Zydus Lifesciences Ltd consolidated sales up 4.94% on year in Q2FY2026
11-Aug-2026, 03:49
Zydus Lifesciences Ltd share price gained 0.49% to Rs 1120.7 after the company's net profit tanked by 28.99% to Rs 952.4 crore, while revenue from operations slightly gained 4.94% to Rs 7802.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has marginally improved by 0.56% over last one week and climbed by 13.27% in last one month while the market capitalization of Zydus Lifesciences Ltd has inched up 0.20% and 18.32% in the same period respectively. Profit before tax (PBT) of Zydus Lifesciences Ltd stood at Rs 1306.6 crore in Q2 FY26, plunging by 31.97% year-on-year, and tumbling by 21.27% quarter-on-quarter. EBITDA came in at Rs 1823 crore, slipping 5.70% YoY and nosediving by 24.66% sequentially. Total expenses rose by 19.88% to Rs 6642.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1251.2 crore, marginally falling by 7.13% YoY, while employee benefits expense was at Rs 1368.2 crore, rising by 10.45% YoY. For the TTM ended FY26, revenue from operations grew 18.37% to Rs 26719.7 crore, while net profit grew slightly 8.92% to Rs 5026.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 728020% to Rs 7965.6 crore, and PBT saw a minor gain of 9.86% to Rs 6621.1 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2116.6 crore in FY26, as against Rs 6781.1 crore in FY25. Zydus Lifesciences Ltd surged by 17.29% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.
Zydus Lifesciences Ltd share price gained 0.49% to Rs 1120.7 after the company's net profit tanked by 28.99% to Rs 952.4 crore, while revenue from operations slightly gained 4.94% to Rs 7802.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has marginally improved by 0.56% over last one week and climbed by 13.27% in last one month while the market capitalization of Zydus Lifesciences Ltd has inched up 0.20% and 18.32% in the same period respectively. Profit before tax (PBT) of Zydus Lifesciences Ltd stood at Rs 1306.6 crore in Q2 FY26, plunging by 31.97% year-on-year, and tumbling by 21.27% quarter-on-quarter. EBITDA came in at Rs 1823 crore, slipping 5.70% YoY and nosediving by 24.66% sequentially. Total expenses rose by 19.88% to Rs 6642.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1251.2 crore, marginally falling by 7.13% YoY, while employee benefits expense was at Rs 1368.2 crore, rising by 10.45% YoY. For the TTM ended FY26, revenue from operations grew 18.37% to Rs 26719.7 crore, while net profit grew slightly 8.92% to Rs 5026.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 728020% to Rs 7965.6 crore, and PBT saw a minor gain of 9.86% to Rs 6621.1 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2116.6 crore in FY26, as against Rs 6781.1 crore in FY25. Zydus Lifesciences Ltd surged by 17.29% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.